Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Solid tumor treatment efficacy is limited by drug delivery barriers within the tumor microenvironment (TME).
• Multifunctional nanotherapeutics aim to overcome these barriers via optimized pharmacokinetics, targeted delivery, and controlled release.
• Significant challenges remain in translating nanotherapeutic strategies to clinical success, including TME heterogeneity and manufacturing complexity.

Purpose of the Study:

• To organize nanoplatforms based on TME phenotype-informed design logic.
• To critically examine current nanotherapeutic strategies for solid tumors.
• To discuss future directions for nanotherapeutic development and clinical translation.

Main Methods:

• Literature review and critical analysis of nanotherapeutic strategies.
• Organization of nanoplatforms by TME barriers and design objectives.
• Examination of pharmacokinetic, vascular, stromal, immune, and theranostic approaches.

Main Results:

• Nanotherapeutics are designed to address TME barriers like vascular access, stromal penetration, and immune evasion.
• Key challenges include heterogeneous enhanced permeability and retention (EPR) effects, uncertain active targeting translation, and complex manufacturing.
• A phenotype-informed design logic is proposed to link biological barriers to design objectives and translational constraints.

Conclusions:

• Future nanotherapeutic progress depends on phenotype-matched and evidence-stratified deployment rather than indiscriminate functional stacking.
• Rational platform simplification and consideration of administration routes, patient stratification, and safety are crucial.
• A systematic framework is needed to guide the rational design and clinical translation of nanotherapeutics for solid tumors.